Refocusing HIV antibodies to target parts that block many strains
Official title: Redirecting Antibody Epitope Specificity with HIV-1 Env-Based Immunization
Funded at Wistar Institute · NIH-11411742 · Data updated 2026-11-12
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 1, 2026 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $887,239 |
| NIH project number | 1R01AI200748-01 |
| Project ID | NIH-11411742 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ultimately the approach would be for people at risk of HIV exposure, but this grant focuses on laboratory and animal work rather than enrolling patients now.
✕Less likely to help
People already living with HIV or those needing immediate clinical treatment would not gain direct short-term benefits from this basic research.
What this research studies
If I were following this work, I would learn that scientists are redesigning pieces of the HIV envelope protein to push antibodies toward the virus' vulnerable sites instead of the irrelevant base. They are testing engineered Env proteins in the lab and in animal models and giving repeated immunizations to see how B cells and antibody lineages change. Researchers track how antibodies mutate over time to see if non-neutralizing responses can be redirected to become broadly neutralizing. The aim is to develop vaccine designs that guide the immune system to produce antibodies effective against many HIV strains.
Why it matters
Potential benefit: If successful, this could lead to vaccines that generate broadly neutralizing antibodies and provide stronger protection against diverse HIV strains.
How similar studies have gone: Prior animal and early human work shows the Env base commonly draws non-neutralizing antibodies, but preliminary data from this team indicate antibody lineages can be redirected, making the approach promising though still experimental.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Escolano, Amelia — Wistar Institute
- Study coordinator: Escolano, Amelia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.